Yen-Ting Liu, Yi-Hsing Chen, Chen-Han Chang, Hsiang-Kuang Tony Liang
{"title":"Recurrent FGFR3 fusion glioblastoma treated with pemigatinib: a case report and review of the literature","authors":"Yen-Ting Liu, Yi-Hsing Chen, Chen-Han Chang, Hsiang-Kuang Tony Liang","doi":"10.1093/noajnl/vdae072","DOIUrl":null,"url":null,"abstract":"\n This study presents an evaluation of pemigatinib, a selective inhibitor of FGFR1-3, in the management of recurrent FGFR3 fusion glioblastoma, underlining its potential as a precision therapy. Introduced in a 53-year-old man after standard therapies failed and genomic profiling identified an FGFR3-TACC3 fusion, pemigatinib induced a partial disease response and neurological improvement but also posed a financial burden. The case emphasizes the role of precision medicine in neuro-oncology, and supports further research into the integration of pemigatinib into glioblastoma treatment protocols.","PeriodicalId":19138,"journal":{"name":"Neuro-oncology Advances","volume":"71 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology Advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This study presents an evaluation of pemigatinib, a selective inhibitor of FGFR1-3, in the management of recurrent FGFR3 fusion glioblastoma, underlining its potential as a precision therapy. Introduced in a 53-year-old man after standard therapies failed and genomic profiling identified an FGFR3-TACC3 fusion, pemigatinib induced a partial disease response and neurological improvement but also posed a financial burden. The case emphasizes the role of precision medicine in neuro-oncology, and supports further research into the integration of pemigatinib into glioblastoma treatment protocols.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
